Y. Zhu, B. Pandya, and H. Choi, Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey, Arthritis and rheumatism. Epub, vol.6330, issue.10, pp.3136-3177, 2007.

E. Fels and J. Sundy, Refractory gout: what is it and what to do about it? Current opinion in rheumatology, Epub, vol.2020, issue.2, pp.198-202, 2008.

N. Schlesinger, Difficult-to-Treat Gouty Arthritis, Drugs, vol.69, issue.6887, pp.1413-1452, 2011.
DOI : 10.1136/ard.2010.136218

A. So, D. Smedt, T. Revaz, S. Tschopp, and J. , A pilot study of IL-1 inhibition by anakinra in acute gout, Arthritis Research & Therapy, vol.9, issue.2, pp.28-17352828, 2007.
DOI : 10.1186/ar2143

F. Committee, Summary Minutes of the Arthritis Advisory Committee Meeting, 2011.

R. Paniagua, O. Sharpe, P. Ho, S. Chan, A. Chang et al., Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis, Journal of Clinical Investigation, vol.116, issue.10, pp.2633-2675, 2006.
DOI : 10.1172/JCI28546.

K. Eklund and H. Joensuu, Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases, Annals of Medicine, vol.35, issue.5, pp.362-369, 2003.
DOI : 10.1080/07853890310001339

A. Juurikivi, C. Sandler, K. Lindstedt, P. Kovanen, T. Juutilainen et al., Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1126-1157, 2005.
DOI : 10.1136/ard.2004.029835

K. Miyachi, A. Ihara, R. Hankins, R. Murai, S. Maehiro et al., Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia, Clinical Rheumatology, vol.22, issue.4-5
DOI : 10.1007/s10067-003-0716-3

A. Levitzki, Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance Annual review of pharmacology and toxicology, Epub, vol.531010, pp.161-85, 2012.

L. Reber, T. Marichal, J. Sokolove, P. Starkl, N. Gaudenzio et al., Contribution of mast cellderived interleukin-1beta to uric Acid crystal-induced acute arthritis in mice, Arthritis & rheumatology, vol.6620, issue.1006, pp.2881-91, 2014.

F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, vol.20, issue.7081, pp.237-278, 2006.
DOI : 10.7326/0003-4819-62-4-648
URL : http://www.nature.com/nature/journal/v440/n7081/pdf/nature04516.pdf

S. Gross, S. Gammon, B. Moss, D. Rauch, J. Harding et al., Bioluminescence imaging of myeloperoxidase activity in vivo, Nature Medicine, vol.107, issue.4, pp.455-61, 2009.
DOI : 10.1042/bj3080559

R. Colvin, T. Means, T. Diefenbach, L. Moita, R. Friday et al., Synaptotagmin-mediated vesicle fusion regulates cell migration, Nature Immunology, vol.31, issue.6, pp.495-502, 2010.
DOI : 10.4049/jimmunol.179.4.2223
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951881/pdf

I. Mitroulis, K. Kambas, and R. K. Neutrophils, IL-1beta, and gout: is there a link? Seminars in immunopathology, pp.501-513, 2013.

P. Simkin, J. Bassett, and Q. Lee, Not water, but formalin, dissolves urate crystals in tophaceous tissue samples, J Rheumatol, vol.21, issue.12, pp.2320-2321, 1994.

Y. Zermati, D. Sepulveda, P. Feger, F. Letard, S. Kersual et al., Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms, Oncogene, vol.22, issue.5, pp.660-664, 2003.
DOI : 10.1038/sj.onc.1206120
URL : https://hal.archives-ouvertes.fr/hal-00282566

B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger et al., Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia, New England Journal of Medicine, vol.344, issue.14, pp.1031-1038, 2001.
DOI : 10.1056/NEJM200104053441401

N. Wolff, D. Randle, M. Egorin, J. Minna, R. Ilaria et al., Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer, Clinical Cancer Research, vol.10, issue.10
DOI : 10.1158/1078-0432.CCR-0957-03